Dynavax Technologies Corporation reported first quarter 2020 financial results. HEPLISAV-B net product revenue was $10.5 million, compared to $5.6 million in Q1 2019. Net loss allocable for the first quarter of 2020 was $12.6 million, or $0.15 per basic share and $0.25 per diluted share, compared to a net loss of $39.7 million, or $0.62 per basic and diluted share, for the first quarter of 2019.
HEPLISAV-B net product revenue reached $10.5 million in Q1 2020, a significant increase from $5.6 million in Q1 2019.
Multiple collaborations were established, leveraging Dynavax’s vaccine adjuvant CpG 1018 in coronavirus (COVID-19) vaccine candidates.
Positive interim clinical trial results were reported for HEPLISAV-B in dialysis patients.
Dynavax exceeded the HEPLISAV-B minimum product revenue covenant in its Term Loan Agreement.
Dynavax is focused on driving revenue growth of HEPLISAV-B, generating data to support a unique dosing regimen for patients on hemodialysis, and supporting policy initiatives aimed at protecting more adults through adoption of a two-dose regimen. The company is also leveraging its proprietary vaccine adjuvant, CpG 1018, to support the development of coronavirus vaccines.
Analyze how earnings announcements historically affect stock price performance